PTC
CLDX icon

Private Trust Company’s Celldex Therapeutics CLDX Stock Holding History

Private Trust Company’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4
Closed -$1K – 451
2014
Q3 		$1K Hold
4
– – ﹤0.01% 1711
2014
Q2 		$1K Hold
4
– – ﹤0.01% 1733
2014
Q1 		$1K Hold
4
– – ﹤0.01% 1607
2013
Q4 		$2K Buy
4
+2
+100% +$770 ﹤0.01% 1445
2013
Q3 		$1K Buy
+2
New +$686 ﹤0.01% 1560

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Private Trust Company's CLDX Position: Q4 2014 in Review

Private Trust Company sold out of Celldex Therapeutics (CLDX) in Q4 2014, closing a stake of 4 shares — an estimated $1K sold.

Private Trust Company first reported a position in CLDX in Q3 2013 and held it in 5 quarters. The position peaked at $2K in Q4 2013. 163 funds tracked by Wall St. Rank hold CLDX as of Q4 2014.

  • Private Trust Company reported no remaining Celldex Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Private Trust Company sold 4 Celldex Therapeutics shares in Q4 2014, an estimated $1K.
  • Private Trust Company first reported a position in Celldex Therapeutics in Q3 2013 and held it in 5 quarters.
  • Private Trust Company's Celldex Therapeutics position peaked at $2K in Q4 2013.
  • 163 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2014.

Based on Private Trust Company's 13F filing for Q4 2014, filed 28 Jan 2015.